Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dipipanone→

Dipipanone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
467-83-4
Molecular formula
C24H31NO
Molecular weight
349.5 g/mol
Drug class
Synthetic opioid analgesicmu-opioid receptor agonist
Mechanism of action
Activates mu-opioid receptors in the central nervous system, inhibiting nociceptive neurotransmission and producing analgesia, sedation and respiratory depression.
Indications / reported uses
  • Historical use for severe pain in countries where dipipanone-containing products were authorised, often in combination with cyclizine; controlled-drug restrictions and product availability are jurisdiction-specific

Sources: NLM MeSH — Dipipanone · UK Home Office — Controlled drugs list · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dipipanone Environmental Risk Assessment (ERA) (the Dipipanone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.